Focused radiosurgery extends survival for small cell lung cancer patients with brain metastases
Patients with small cell lung cancer (SCLC) that had spread to the brain lived a median of 17 months after focused stereotactic radiosurgery, compared with nine months after an advanced form of whole brain radiation therapy, an unexpected secondary finding from the first randomized phase 3 trial to compare the treatment approaches in this population.
Read original article on The Medical News →Related news
-
What older adults do on screens may matter more than total screen time
United Kingdom
-
Social connection has a price, and it varies from person to person
United Kingdom
-
Multimorbidity identified in most Japanese home care patients
United Kingdom
-
People make first choices faster as outcomes grow less predictable, study finds
United Kingdom
-
Can exercise do more harm than good? Mini-heart research is uncovering new answers
United Kingdom
-
Global survey reveals major variation in the measurement of bone and mineral metabolism biomarkers
United Kingdom
-
Exercise program supports better attention and slows biological aging in breast cancer survivors
United Kingdom
-
Cell network reveals how pancreatic cancer drives muscle and fat loss
United Kingdom